scispace - formally typeset
Open AccessJournal ArticleDOI

Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients

Reads0
Chats0
TLDR
LVEF is a powerful predictor of cardiovascular outcome in heart failure patients across a broad spectrum of ventricular function, and once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk inheart failure patients.
Abstract
Background— Left ventricular function is a principal determinant of cardiovascular risk in patients with heart failure. The growing number of patients with preserved systolic function heart failure underscores the importance of understanding the relationship between ejection fraction and risk. Methods and Results— We studied 7599 patients with a broad spectrum of symptomatic heart failure enrolled in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. All patients were randomized to candesartan at a target dose of 32 mg once daily or matching placebo and followed up for a median of 38 months. We related left ventricular ejection fraction (LVEF), measured before randomization at the sites, to cardiovascular outcomes and causes of death. Mean LVEF in patients enrolled in CHARM was 38.8±14.9% (median LVEF 36%). Patients with lower LVEF tended to have higher baseline New York Heart Association class. The hazard ratio for all-cause mortality increased by 39% fo...

read more

Citations
More filters
Journal ArticleDOI

Global Public Health Burden of Heart Failure.

TL;DR: In this article, the authors focus on the global epidemiology of heart failure, providing data about prevalence, incidence, mortality and morbidity worldwide, and show geographic variations, depending on the different aetiologies and clinical characteristics observed among patients with heart failure.
References
More filters
Journal ArticleDOI

Effect of carvedilol on survival in severe chronic heart failure.

TL;DR: The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial.
Journal ArticleDOI

Effect of carvedilol on survival in severe chronic heart failure

TL;DR: In this article, the authors evaluated 2289 patients who had symptoms of heart failure at rest or on minimal exertion, who were clinically euvolemic, and who had an ejection fraction of less than 25 percent.
Journal ArticleDOI

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

TL;DR: Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials.
Related Papers (5)
Trending Questions (1)
How long can you live with an ejection fraction of 25?

Nevertheless, once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk in heart failure patients.